drugset / Trial / NCT03237156

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

NCT03237156

Phase 1 Completed 24 enrolled Takeda
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male participants.

Timeline

Start
2017-08-07
Primary completion
2017-10-07
Completion
2017-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Trazpiroben Small molecule 10 mg Oral
Subject Trazpiroben Small molecule 50 mg Oral
Subject Trazpiroben Small molecule 100 mg Oral

Indications

No indication recorded.